Fas (CD95) induces rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1 from macrophages
- 6.4k Downloads
Although Fas (CD95) is recognized as a death receptor that induces apoptosis, recent studies indicate that the Fas/FasL system can induce pro-inflammatory cytokine production by macrophages independent of conventional caspase-mediated apoptotic signaling. The precise mechanism(s) by which Fas activates macrophage inflammation is unknown. We hypothesized that Fas stimulates rapid release of high mobility group box 1 (HMGB1) that acts in an autocrine and/or paracrine manner to stimulate pro-inflammatory cytokine production via a Toll-like receptor-4 (TLR4)/Interleukin-1 receptor associated kinase-4 (IRAK4)-dependent mechanism. Following Fas activation, HMGB1 was released within 1 hr from viable RAW267.4 cells and primary murine peritoneal macrophages. HMGB1 release was more rapid following Fas activation compared to LPS stimulation. Neutralization of HMGB1 with an inhibitory anti-HMGB1 monoclonal antibody strongly inhibited Fas-induced production of tumor necrosis factor (TNF) and macrophage inflammatory protein-2 (MIP-2). Both Fas-induced HMGB1 release and associated pro-inflammatory cytokine production were significantly decreased from Tlr4 -/- and Irak4 -/- macrophages, but not Tlr2 -/- macrophages. These findings reveal a novel mechanism underlying Fas-mediated pro-inflammatory physiological responses in macrophages. We conclude that Fas activation induces rapid, TLR4/IRAK4-dependent release of HMGB1 that contributes to Fas-mediated pro-inflammatory cytokine production by viable macrophages.
KeywordsProinflammatory Cytokine Production Translational Research Program Medical Scientist Training Program Apoptotic Programme Cell Death Primary Murine Peritoneal Macrophage
Fas (CD95) is a 48-kDa, type I transmembrane protein member of the TNF receptor family . The endogenous ligand for Fas is FasL (CD178), a 40-kDa, type II homotrimeric transmembrane protein member of the TNF gene family [1, 2]. The Fas/FasL (APO-1/APO-1L; CD95/CD95L) system was first reported, and is generally recognized, as a major regulator of the extrinsic pathway of caspase-dependent apoptosis [3, 4, 5, 6]. Fas-mediated apoptosis has been extensively studied for its non- or anti-inflammatory role in tissue injury and organ dysfunction [7, 8, 9]. However, accumulating evidence indicates that Fas can mediate myeloid differentiation factor 88 (MyD88)/interleukin-1 receptor-associated kinase-4 (IRAK4)-dependent pro-inflammatory responses via mechanisms distinct from its role in apoptotic programmed cell death [10, 11, 12, 13, 14].
HMGB1 protein was first described almost 30 years ago as a non-histone chromosomal protein with high electrophoretic mobility [15, 16]. As a DNA binding protein, HMGB1 is involved in maintenance of nucleosome structure and regulation of gene transcription [17, 18]. In addition to its role in regulation of transcription, HMGB1 has been shown to activate pro-inflammatory responses when released by necrotic cells into the extracellular milieu . HMGB1 has been implicated in the pathogenesis of a number of diseases associated with inflammation and tissue injury, including sepsis [20, 21, 22, 23]. Recent evidence indicates that HMGB1 can be released not only from necrotic cells but also from activated macrophages to act as an 'endogenous dangerous signal' or 'alarmin' . Several cognate cell surface receptors have been proposed for HMGB1, including receptor for advanced glycation end products (RAGE), TLR2 and TLR4 [25, 26, 27]. HMGB1-induced proinflammatory cytokine production by macrophages has been reported to be TLR4-dependent [28, 29, 30].
In this study, we demonstrate that activation of Fas induces rapid release of HMGB1 from a murine macrophage (mϕ) cell line and primary murine peritoneal mϕ that contributes to Fas-induced pro-inflammatory cytokine production. Furthermore, using genetically defined mice, we show that TLR4/IRAK4-dependent mechanisms are involved in Fas-induced HMGB1 release and pro-inflammatory cytokine production by mϕs. These findings identify a novel mechanism for Fas-mediated pro-inflammatory responses and implicate important physiological cross-talk between Fas, TLR4, and HMGB1.
Materials and methods
Recombinant mouse Fas ligand (CD178) was obtained from R&D system (Minneapolis, MN, USA). Anti-mouse Fas monoclonal antibody (mAb) Jo2 IgG2 was obtained from BD Bioscience (Mississauga, ON Canada). Lipopolysaccharide (LPS, Escherichia coli 0111:B4) was obtained from Sigma (St Louis, MO, USA). Inhibitory anti-HMGB1 neutralizing monoclonal antibody was provided by Dr. Huan Yang from the Feinstein Institute for Medical Research (Manhasset, NY, USA) . Mouse IgG2b isotype control (R&D System, MN, USA) was used as a negative control antibody.
Primary murine peritoneal macrophage isolation and culture
Animal use was performed in compliance with current University of Toronto institutional guidelines, and animal protocols were approved by the Animal Care Committee of the University of Toronto. Peritoneal mϕ were obtained by peritoneal lavage from wild type, Tlr2-/-, Tlr4-/-, Irak4 -/- mice (all mice were maintained on the C57BL/6 genetic background; age: 8-10 weeks; weight: 20-25 g) and Fas-deficient Fas lpr mice (The Jackson Laboratory, Maine, USA). Briefly, 10 ml of sterile RPMI was injected into the peritoneal cavity, and the contents of the cavity were gently massaged. A similar volume was then removed from the abdomen, and 2 × 106 cells/well were seeded in a volume of 2 ml/well in a 6-well tissue culture plate.
Cell culture and treatment
The murine mϕ cell line RAW264.7 (American Type Cell Collection, Rockville, MD, USA) and primary murine peritoneal mϕ were maintained in RPMI 1640 (Sigma; Mississauga, ON, Canada), containing 10% heat-inactivated fetal bovine serum (FBS) (Sigma, Mississauga, ON, Canada) supplemented with gentamicin reagent solution (Invitrogen; Burlington, ON, Canada), at 37°C in 5% CO2-enriched air. Cells (2 × 106/well) were plated in 6-well tissue culture plates at a volume of 2 ml/well in RPMI 1640 containing 10% fetal bovine serum and pretreated with or without inhibitory anti-HMGB1 neutralizing monoclonal antibody (IgG2b mAb) (0.25 μg/ml) or a negative isotype (IgG2b) control (IgG2b) mAb (0.25 μg/ml). Macrophages were stimulated with recombinant mouse Fas ligand (mFasL, 0.25 μg/ml), or activating anti-murine Fas mAb Jo2 (IgG2, 0.25 μg/ml), or LPS (0.25 μg/ml). mFasL and mAb Jo2 were pretreated with Detoxi-Del™ Endotoxin Removing Gel (Pierce Biotech: Rockford, IL, USA) to remove any contaminating LPS. Samples of culture supernatant were obtained at multiple time points. Cell count and viability were determined microscopically by 0.4% trypan blue dye exclusion. The concentration of endotoxin in each wells were tested with Prostate LAL (PSD10, MA, USA). In our experiments, clot formed only in the LPS treated group indicating that endotoxin levels in all other groups were less than 0.25 EU/ml.
Cell viability assay
Cell viability was determined by trypan blue exclusion using a Vi-Cell XR Cell Analyzer (Beckman Coulter, CA, USA).
Preparation of cellular extracts
Cells were harvested at the designated times and washed twice with cold PBS; nuclear and cytoplasmic extracts were prepared according to the method of Schreiber et al . Briefly, the cell pellets were resuspended in 400 μl cold buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF). Cells were allowed to swell on ice for 15 min, after which 25 μl of a 10% solution of Nonidet P-40 was added, and the tube was vortexed vigorously for 10 s. The lysate was centrifuge at 4°C at 15000 g for 3 min, and the nuclear pellet was resuspended in 50 μl ice-cold buffer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF). After vigorously rocking at 4°C for 15 min on a shaking platform, the nuclear extract was centrifuged for 5 min at 4°C, and the supernatant was frozen at -80°C. The protein content of the different fractions was determined by Bradford assay.
Concentration of conditioned cell culture medium
After incubation, cell medium were collected and concentrated 10-fold using a 7 ml ICON concentrator (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's protocol. The final protein concentration of cell medium of the negative control group was 5 μg/μl. The concentrated samples were boiled for 5 min and used for detection of HMGB1 by immunoblot analysis.
HMGB1 immunoblot analysis
Proteins in concentrated culture media and cell extracts were resolved on 10% SDS-PAGE and transferred to a polyvinylidene fluoride membrane. After blocking with 5% non-fat milk at room temperature for 1 hr, the transfer membranes were incubated for 1 hr with primary antibodies specific for HMGB1 (Abcam, MA, USA), proliferating cell nuclear antigen (PCNA; BD Biosciences, CA, USA) and β-actin (Cell Signaling, Pickering, ON, CANADA), respectively. After incubation with peroxidase-conjugated secondary antibodies for 1 hr at 25°C, the signals were visualized by 3'-diaminobenzidine detection (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions.
Measurement of cytokine production
The levels of TNF-α and MIP-2 in culture supernatants were measured by cytokine-specific enzyme-linked immunosorbent assay (ELISA) using previously validated DuoSet antibody pairs (R&D Systems, MN, USA) according to the manufacturer's instructions.
All data are presented as mean ± standard deviation (SD). The data were analyzed by the t-test (parametric) and by the Mann-Whitney U test (non-parametric) for comparisons between two independent groups. A P value < 0.05 was considered to be statistically significant.
Activation of Fas induces rapid release of HMGB1 from viable mϕ
In the absence of mFasL, HMGB1 release from wild-type mϕ was not detected at any time. Following stimulation with either mFasL or mAb Jo2, the concentration of HMGB1 released into the medium increased overtime. We observed that the time courses of mFasL and LPS-induced HMGB1 secretion were different. Whereas release of HMGB1 following stimulation could be detected as early as 1 hr following stimulation with mFasL, LPS-induced release of HMGB1 could not be detected until 6 hr (Figure 1B).
To demonstrate conclusively that the release of HMGB1 induced by treatment with either mFasL or mAb Jo2 is Fas-specific, we performed experiments using mϕ from Fas lpr mice which are functionally Fas-deficient. HMGB1 was detected by immunoblot in the culture supernatant of Fas lpr mϕ following treatment with LPS. In contrast, HMGB1 release could not be detected from Fas lpr mϕ stimulated with either mFasL or mAb Jo2 for 12 hr (Figure 1C).
Fas induces translocation of HMGB1 to the cytoplasm of mϕ
Release of HMGB1 contributes to Fas-induced pro-inflammatory cytokine production by mϕ
Fas induced production of pro-inflammatory cytokines is TLR4-dependent
Fas induces HMGB1 release from mϕ via a TLR4/IRAK4-dependent mechanism
HMGB1 has been reported to be actively released by mϕ in response to stimulation with LPS or hydrogen [29, 35]. Our results demonstrate that activation of Fas induces not only active but also rapid release of HMGB1 from viable mϕ via a TLR4/IRAK4-dependent mechanism. Furthermore, the data from this study suggest that released HMGB1 functions in an autocrine and/or paracrine manner to mediate Fas-induced pro-inflammatory production by mϕ. To our knowledge, these data are the first to implicate HMGB1 in Fas-mediated physiological responses. These insights significantly advance our understanding of physiological roles of both the Fas/FasL system and HMGB1 in activation of host innate immune responses.
Although generally recognized for its role in mediating caspase-dependent, apoptotic programmed cell death [1, 2, 3], the Fas/FasL system is increasingly recognized for its ability to induce pro-inflammatory cytokine production by mϕ via MyD88-dependent, caspase-independent mechanisms [13, 14, 36, 37]. A previous study demonstrated that Fas ligation enhances IL-R1/TLR4 signaling to promote macrophage-mediated inflammation . Specifically, interruption of Fas-FasL signaling was shown to suppress both NF-κB activation and cytokine expression induced by IL-1 and LPS in primary human and murine mϕ . Furthermore, it was suggested that this cross-talk between Fas and IL-R1/TLR4 was mediated by interaction of Fas-associated death domain (FADD) with MyD88. The biological importance of this cross-talk was supported by another study in which sustained functional deficiency of the Fas/FasL system in mice attenuated sustained LPS-induced lung inflammation .
The release of HMGB1 into the extracellular environment, where it can function as an endogenous danger signal or 'alarmin' to promote inflammation has been implicated in a number of diseases associated with tissue injury, including sepsis and acute lung injury [28, 29]. In the current study, we demonstrated that activation of Fas induced rapid (within 1 hr) release of HMGB1 from RAW264.7 (a murine macrophage cell line) and primary murine peritoneal mϕ (Figure 1). Similar rapid, active release HMGB1 has also been reported in experimental brain ischemia . Following activation of Fas, HMGB1 was detected in the cytoplasm of mϕ, consistent with a process of nuclear-cytoplasmic translocation as previously reported for LPS stimulation . Following this translocation event, HMGB1 was subsequently detected in the extracellular milieu of mϕ (Figure 3). Importantly, Fas-induced HMGB1 release was not associated with cell death (Figure 2) and was remarkably more rapid than HMGB1 release induced by LPS (Figure 1), a known stimulus for HMGB1 release from mϕ [32, 40].
Surprisingly, experiments performed employing murine mϕ with targeted genetic deletions of Tlr2, Tlr4, and Irak4 demonstrated that the Fas/FasL system induced HMGB1 release primarily via a TLR4/IRAK4-dependent mechanism (Figure 6). Interestingly, previous studies have demonstrated TLR4-mediated activation of HMGB1 translocation and subsequent release of HMGB1 from distinct cell types, including mϕ [29, 40, 41, 42, 43]. Taken together, our data are consistent with a proposed 3-step model for Fas-mediated activation of pro-inflammatory cytokine production by mϕ: 1) Fas-induced nuclear-cytoplasmic translocation of HMGB1; 2) subsequent release of cytoplasmic HMGB1 by Fas-activated mϕ; and 3) autocine/paracrine-mediated feedback by HMGB1 to activate TLR4 and promote TLR4/IRAK4-dependent pro-inflammatory cytokine production. Based on our observation that mϕ viability was not affected by Fas activation, we believe that Fas-mediated HMGB1 release occurs via the previously described active pathway for HMGB1 release from viable cells [29, 40, 41, 42, 43]. This pathway appears to be calcium/calmodulin-dependent and involve HMGB1 hyperacetylation and/or phosphorylation [28, 40, 41, 42, 43]. Overall, our findings are consistent with previous reports that the TLR4/MyD88/IRAK4 complex not only serves to detect and initiate intracellular signaling in response to exogenous pathogens but also functions to secrete HMGB1 from mϕ into the extracellular environment [27, 28, 29, 40, 41, 42, 43].
Our current study strongly supports a role for HMGB1, acting as an autocrine and/or paracrine mediator, in Fas-induced pro-inflammatory cytokine production by mϕ. Neutralization of HMGB1 using an inhibitory anti-HMGB1 mAb significantly decreased Fas-induced production of TNF-α and MIP-2 by primary murine peritoneal mϕ (Figure 4). The observation that Fas-induced production of TNF-α and MIP-2 was markedly decreased in Tlr4 -/- mϕ vs wild-type mϕ (Figure 5) is consistent with previous reports that HMGB1 may function predominately as a TLR4 agonist to promote macrophage-mediated inflammation [26, 28, 30, 44, 45]. However, our results do not exclude the possibility that TLR2 and/or RAGE may serve as receptors for HMGB1 on mϕ [25, 26, 27, 44].
Previous studies have identified several mechanisms for Fas-induced pro-inflammatory responses in mϕ. Miwa et al. reported that Fas induced release of IL-1β from mϕ via a caspase 1-independent pathway to promote inflammation . Ma et al. extended our understanding of Fas-mediated inflammation by demonstrating cross-talk in mϕ, whereby Fas enhanced signaling via either the IL-1R1 and/or TLR4 pathway to promote chronic inflammation . Previous studies from our group demonstrated that Fas could activate pro-inflammatory cytokine production by mϕ via a MyD88-dependent, caspase-independent pathway . Our current study has identified a unique mechanism for Fas-mediated inflammation, in which HMGB1 is rapidly released by viable mϕ via a TLR4/IRAK4-dependent mechanism and functions in an autocrine and/or paracrine manner to stimulate pro-inflammatory cytokine production.
In summary, this study demonstrates a previously undescribed mechanism for Fas-mediated inflammation involving rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1 from mϕ. Furthermore, our observations implicate novel physiological cross-talk between Fas, TLR4, and HMGB1 in the pathogenesis of mϕ-mediated inflammation. These results suggest the potential utility of therapeutic interventions directed against HMGB1 in pathophysiological disease states associated with mϕ-mediated inflammation and tissue injury.
About the authors
W. Conrad Liles, M.D., Ph.D. Professor and Vice-Chair of Medicine; Director, Division of Infectious Diseases; Senior Scientist, McLaughlin Centre for Molecular Medicine; Senior Scientist, McLaughlin-Rotman Centre for Global Health; Canada Research Chair in Infectious Diseases and Inflammation; University of Toronto
WCL received his undergraduate education at Williams College (Williamstown, MA, USA), then entered the National Institutes of Health (NIH)-sponsored MD-PhD program (Medical Scientist Training Program) at the University of Washington and graduated in 1987 with an MD and PhD in pharmacology. Following residency in Internal Medicine at Massachusetts General Hospital from 1987-1990, he returned to the University of Washington where he served as Chief Medical Resident in 1991 and as a Fellow in Infectious Diseases from 1992-1995. In 1996, he was named to the faculty at the University of Washington as Assistant Professor of Medicine in the Division of Allergy and Infectious Diseases and rose to the rank of Professor of Medicine and Adjunct Professor of Pathology. In March 2006, WCL moved to the University of Toronto to assume the positions of Vice-Chair of Medicine and Director, Division of Infectious Diseases. He was attracted to the University of Toronto by the opportunities to build translational research programs in sepsis, inflammation, emerging infectious diseases of public health importance. He is the recipient of a Canada Research Chair in Inflammation and Infectious Diseases and a member of the McLaughlin Centre for Molecular Medicine, the McLaughlin-Rotman Centre for Global Health, and the Toronto General Research Institute. As author of more than 135 peer-reviewed manuscripts and 35 book chapters, WCL maintains an active translational research program in host defense, inflammation, innate immunity, sepsis, immunodeficiency disorders, and immunomodulatory therapy, while serving as a chartered member of the Immunity and Host Defense Study Section of the NIH. In 2004, WCL received the Outstanding Investigator Award from the Western Society for Clinical Investigation (WSCI). He has been elected to Fellowship in the American College of Physicians (ACP) and the Infectious Diseases Society of America (IDSA).
This work was supported by Canada Research Chairs from the Canadian Institutes of Health Research (WCL and KCK), National Institutes of Health grant P60 HL73996 (WCL), and research funding from the McLaughlin Centre for Molecular Medicine, University Health Network, University of Toronto.
- 12.Oliveira GM, Diniz RL, Batista W, Batista M, Bani M, Correa C, de Araújo-Jorge TC, Henriques-Pons A: Fas ligand-dependent inflammatory regulation in acute myocarditis induced by Trypanosoma cruzi infection. Am J Pathol. 2007, 171: 79-86. 10.2353/ajpath.2007.060643.PubMedPubMedCentralCrossRefGoogle Scholar
- 21.Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ: High mobility group 1 protein (HMG1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000, 192: 565-570. 10.1084/jem.192.4.565.PubMedPubMedCentralCrossRefGoogle Scholar
- 22.Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48: 971-981. 10.1002/art.10859.PubMedCrossRefGoogle Scholar
- 23.Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal BA, Khademi M, Wallström E, Lobell A, Brundin L, Lassmann H, Harris RA: Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008, 84: 1248-1255. 10.1189/jlb.1207844.PubMedCrossRefGoogle Scholar
- 26.Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: Involvement of TLR2 and TLR4 in cellular activation by high mobility group box 1 protein (HMGB1). J Biol Chem. 2004, 279: 7370-7376. 10.1074/jbc.M306793200.PubMedCrossRefGoogle Scholar
- 29.Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz DB, Geller DA, Rosengart MR, Billiar TR: HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med. 2007, 204: 2913-2923. 10.1084/jem.20070247.PubMedPubMedCentralCrossRefGoogle Scholar
- 38.Matute-Bello G, Winn RK, Martin TR, Liles WC: Sustained polysaccharide-induced lung inflammation in mice is attenuated by functional deficiency of the Fas/Fas ligand system. Clin Diag Lab Immunol. 2004, 11: 358-361.Google Scholar
- 43.Zhang X, Wheeler D, Tang Y, Guo L, Shapiro RA, Ribar TJ, Means AR, Billiar TR, Angus DC, Rosengart MR: Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J Immunol. 2008, 181: 5015-5023.PubMedPubMedCentralCrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.